Company intelligence / Profile preview

XtRNA Bio

Amsterdam, North Holland, Netherlandsnlc.health ↗
Ownership
Private
Development stage
Preclinical
01

Overview

XtRNA Bio is a pioneering biotechnology company focused on developing transfer RNA (tRNA) therapeutics to treat rare genetic diseases, with a primary focus on Charcot-Marie-Tooth (CMT) disease. Co-founded by Professor Erik Storkebaum and NLC Health Ventures as a spin-out from Radboud University, the company leverages a dual-modality tRNA platform that enables both tRNA elevation and suppression therapies. Its lead program is a preclinical-stage viral gene therapy (AAV9-tRNAGly) designed to treat Charcot-Marie-Tooth disease type 2D (CMT2D) by restoring the cellular tRNA pool and rebalancing protein translation. Backed by funding from the CMT Research Foundation and NLC Health Ventures, XtRNA Bio aims to expand its platform to address other forms of CMT and genetic disorders caused by premature stop codons.

Therapeutic areas
Rare Diseases
Modalities
Gene therapyRNA therapyBiologic
Industry
Biotech
02

Drug pipeline

1 asset
03

Partnerships

CMT Research FoundationRadboud UniversityNLC Health Ventures

Sources

  1. Other public source
  2. Other public source
  3. Other public source
  4. Other public source
  5. Other public source
  6. Other public source
  7. Other public source

Full sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on XtRNA Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on XtRNA Bio.

Work at XtRNA Bio? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call